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Abstract
Background: The association between HIV infection and invasive cervical cancer that has been reported may
reflect differential prevalence of human papillomavirus (HPV) infection or uncontrolled confounding. We conducted
a case-control study in a West African population to assess the relationship between HIV infection and invasive
cervical cancer, taking into account HPV infection and other potential risk factors for cervical cancer.
Methods: Women with invasive cervical cancer (cases) or normal cervical cytology (controls) were recruited in a
hospital-based case-control study in Abidjan, Côte d’Ivoire. Odds ratios and 95% confidence intervals (CI) were
estimated in logistic regression analyses controlling for important cofactors.
Results: HIV infection was noted in 22/132 (16.7%) cases and 10/120 (8.3%) controls (p = 0.048). High-risk HPV
infection was detected in cervical tumor samples from 89.4% of case-participants and in cervical cytology samples
in 31.1% of control-participants. In logistic regression analysis, HIV infection was associated with cervical cancer in
women with HPV (OR 3.4; 95% CI 1.1-10.8). Among women aged ≤ 40 years, risk factors for cervical cancer were
high-risk HPV infection (OR 49.3; 95% CI 8.2-295.7); parity > 2 (OR 7.0; 95% CI 1.9-25.7) and HIV infection (OR 4.5;
95% CI 1.5-13.6). Among women aged > 40 years, high-risk HPV infection (OR 23.5; 95% CI 9.1-60.6) and parity > 2
(OR 5.5; 95% CI 2.3-13.4), but association with HIV infection was not statistically significant.
Conclusions: These data support the hypothesis that HIV infection is a cofactor for cervical cancer in women with
HPV infection, and, as in all populations, the need for promoting cervical screening in populations with high
prevalence of HIV infection.
Background
In sub-Saharan Africa, age-standardized incidence of
cervical cancer is high, ranging from 29.3 (West Africa)
to 42.7 (southern Africa) per 100,000 women [1]. The
development of cervical cancer is the result of interac-
tion of systemic and local cofactors that facilitate malig-
nant transformation of cervical cells, with HPV infection
as a necessary factor [2]. Based on strength of associa-
tion with cervical cancer, genital HPVs have been cate-
gorized by risk of acting as carcinogens in the
development of cervical cancers. High-risk or oncogenic
types include HPV types 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 66, 68, 73 and 82; low-risk types include
HPV types 6, 11, 42, 43, 44, 54, 61, 70, 72, 81 [3]. Exam-
ples of factors other than HPV that have been suggested
as potential modulators of cervical cancer development
include age and parity [4,5], cigarette smoking [6], long-
term oral contraceptive use [7], and host genetics and
immunological factors [8].
The incidence of cervical cancer has been changing at
a global level, with increasing incidence in women
below 40 years of age [9,10]. This may reflect age-cohort
effects and the emergence of more aggressive histologies
with a shorter natural history, possibly the result of
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screening/awareness resulting in earlier detection of cer-
vical cancer.
In HIV-infected women, there is an increased risk of
HPV infection and squamous intraepithelial lesions
(SIL), the precursor of cervical cancer [11,12]. Since
1993, the revised CDC AIDS case definition has
included the development of cervical cancer in an HIV-
infected person as a sufficient criterion for AIDS, even
in the absence of an opportunistic infection [13].
Numerous studies have analyzed the association of HIV
infection and cervical cancer [14-16]. Although positive
associations between HIV infection and cervical cancer
have been demonstrated [15-18], studies evaluating the
strength of this association among African women have
had differing conclusions [14-16,18,19]. It has been pro-
posed that lack of excess risk of invasive cervical cancer
among HIV-infected women in some populations may
reflect the competing risk of mortality from other condi-
tions associated with HIV infection [20].
Studies of HIV infection and invasive cervical cancer
to date have tended to be limited by lack of information
on presence of HPV DNA in cervical samples of study
participants, and focused on quantifying the effect of
HIV infection relative to other cofactors in the presence
of HPV infection. We conducted a case-control study in
a West African population to assess the relationship
between cervical cancer and HIV infection, taking into
account the presence of high-risk HPV infection and
other cofactors such as age, parity, and lifetime number
of sexual partners. In Côte d’Ivoire, the study setting,
the annual incidence of cervical cancer was approxi-
mately 24.2 per 100,000 [21] during the study period,
and the prevalence of HIV infection among pregnant
women attending antenatal clinics, an approximation of
the prevalence in the general population, was 10% [22].
Methods
Study design and data collection
Over a two-and-a half-year period, all women aged 18-
70 years who presented with cervical lesions at the
gynecology and oncology services at two tertiary hospi-
tals in Abidjan, Côte d’Ivoire were asked to participate.
These university teaching hospitals are the principal
referral sites for patients with suspected malignancies in
Abidjan. Controls were recruited from consecutive eligi-
ble women attending the oncology and general surgery
outpatient clinics for post-surgery follow-up evaluation;
the principal reasons for their admissions were trauma,
abdominal surgery, or breast cancer. None of the
patients had evidence of Kaposi sarcoma or non-Hodg-
kin lymphoma. Eligibility criteria included being aged
18-70 years, having an intact cervix, and having no cur-
rent or past history of cervical disease. Cases and
controls were not individually matched for age, place of
residence, or economic status.
All consenting women were interviewed and examined
by study personnel, using a standardized questionnaire.
Demographic, socioeconomic, reproductive and beha-
vioral data were obtained. Blood samples were collected
by venipuncture and a physician performed a complete
physical and pelvic examination and collected cervical
specimens after visualizing the cervix. For all partici-
pants, endocervical and ectocervical cells were collected
with a Cytobroom (Cytyc, Malborough, MA) and trans-
ferred to PreservCyt™ liquid collection media (Cytyc).
For women with suspected cancer, the cervical lesion
was biopsied and clinical stage was determined using
the 1986 International Federation of Gynecology and
Obstetrics (FIGO) architectural staging system [23].
Informed consent for the overall study was obtained
from all study participants. All study participants
received free clinical evaluation and treatment as indi-
cated by their attending physicians. The study was
reviewed and approved by the ethics committee of the
Côte d’Ivoire Ministry of Public Health and by the Insti-
tutional Review Board of the Centers for Diseases
Control and Prevention.
Definition of case and control
Clinical and pathology data for all participants were
reviewed to determine final inclusion into the study.
Case-participants were required to have histologically
confirmed primary cervical cancer. Advanced disease
was defined as FIGO stage III or higher [23]. Control-
participants were required to have normal cervical cytol-
ogy confirmed in the same institutions as those in which
the case-participants were patients.
Laboratory methods
HIV serology and CD4 counts
Serum was tested for HIV-1 and HIV-2 antibodies by
enzyme-linked immunosorbent assay (ELISA) according
to a standardized algorithm [24,25]. Seropositivity and
type-specific diagnosis for HIV-1 and HIV-2 infections
were determined by reactivity in synthetic peptide-based
line immunoassay or combination of monospecific
ELISA tests. In Côte d’Ivoire, this HIV testing algorithm
was found to have 99% sensitivity and specificity [26].
CD4 lymphocyte phenotyping was performed using a
FACScan flow cytometer (Becton Dickinson, San Jose,
CA), on EDTA-collected peripheral blood.
Cervical samples and HPV DNA detection
Cervical samples and biopsy specimen were sent to the
local reference pathology laboratory in Abidjan, and the
Centers for Disease Control and Prevention (CDC)
laboratory in Atlanta, Georgia. PreservCyt™ samples
were shipped at ambient temperature to CDC and used
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smears were read in a diagnostic cytology laboratory
using Bethesda 1988 criteria [27]. Residual cellular mate-
rial was collected by centrifugation, washed in phos-
phate buffered saline (PBS), re-suspended in 1.5 mL
PBS, and stored at -20°C until extraction.
Cervical biopsy tissue specimens were divided in half
and transported in formalin. One half was sent to the
local pathology laboratory for clinical diagnosis. The
other half was transferred to 50% alcohol 1% formalin
and shipped at ambient temperature to CDC for proces-
sing. At CDC, tissues were trimmed for processing to
paraffin blocks, and serial sections were cut from each
block. The first and last sections were H&E stained and
reviewed to determine research diagnosis. Discrepancies
(benign vs. malignant) between clinical and research
diagnoses were resolved through consensus after
exchange of tissue blocks between the pathology labs.
Intervening sections were used for HPV testing by in situ
hybridization (ISH) and polymerase chain reaction (PCR).
HPV DNA was extracted from 0.5 ml of the stored
cervical cytology samples and from two de-paraffinized
5-μ sections of tumor using the QIAmp DNA Mini Kit
(Qiagen Inc., Valencia, CA) and concentrated in a Cen-
tricon Centrifugal Filter Device YM-100 (Millipore Cor-
p o r a t i o n ,B e d f o r dM A )t o2 5μL. A 5-μLa l i q u o tw a s
used in the L1 consensus PCR assay (PGMY09 and
PGMY11 primer system [28], followed by typing in the
Roche line probe assay [29]. Colorimetric ISH for HPV
types 6/11, 16, 18, 31, 33 and 35 was performed on for-
malin-fixed paraffin-embedded sections as previously
described [30]. The HPV status for cases was based on
combined results from cytology PCR, tumor PCR, and
tumor ISH. A case was considered positive when HPV
was detected in one or more samples. In the event of a
type discrepancy, the result of the tumor PCR was used.
The HPV status for controls was based on the PCR
result from the cytology sample.
Statistical analyses
Statistical analyses were performed using PC SAS (ver-
sion 6.12, SAS Institute, Cary, NC) software. The out-
come was histologically confirmed cervical cancer, and
the primary risk factor of interest was HIV infection,
stratified into two main groups of seroreactivity including
three categories of reactivity: HIV-1 positive, HIV-2 posi-
tive, and dually-reactive. Because HIV-2 is more indolent
than HIV-1 in its effects on the immune system and
related pathologies, those who were HIV-1 or dually
reactive were combined into one group and association
with cervical cancer assessed for the two main groups of
seroreactivity, i.e., HIV-1-positive or dually reactive, and
HIV-2-positive. Because of the small sample size in a
final subgroup analysis by age group, HIV-positive
sub-groups were pooled together in one group, and asso-
ciations with cervical cancer were explored with HIV-
negative as the reference. Other potential risk factors
considered included age (included as continuous vari-
able), socioeconomic status, number of lifetime sexual
partners, parity, (included as categorical variables) and
presence of high-risk HPV DNA (HPV types 16, 18, 31,
33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82).
In univariate analysis, we compared the characteristics
of women with cervical cancer from each of the two
hospitals, and then the characteristics of cases and con-
trol participants. We then assessed HIV covariates
among control participants and the association between
HIV infection and presence of high-risk HPV DNA.
Comparisons were made using Wilcoxon-rank sum tests
for continuous variables, and for categorical variables,
C h iS q u a r eo rF i s h e re x a c tt e s tw h e r ea p p r o p r i a t e[ 3 1 ] .
The association of potential risk factors and cervical
cancer was assessed by the crude odds ratios and
respective 95% confidence intervals.
Multivariate logistic regression analyses were per-
formed to evaluate the independent association between
cervical cancer and risk factors that had been identified
in univariate analyses. The variables included in logistic
regression models were those that were known to be
associated with cervical cancer from previous studies
and were found to be associated with both cervical can-
cer and HIV infection in these data. Different models
were used in logistic regression analyses. First, we used
a model that included age, socioeconomic status, and
lifetime number of sexual partners, parity, and presence
of high-risk HPV DNA and HIV infection to assess the
independent effect of HIV infection taking into account
all other cofactors. Second, because HPV sequences are
found in more than 99% of cervical cancers worldwide
[32], we assumed that our HPV-negative cervical can-
cers were false negatives, and excluded HPV infection
from the model in subsequent analyses assessing effect
of HIV infection on cervical cancer. Third, the analysis
was restricted to cases and control participants with
high-risk HPV infection, and separate logistic regression
analyses were done according to age group, accounting
for the differential age distribution of case and control
participants, and the strong link between age and HIV
infection. Fourth, we compared HIV-positive and HIV-
negative women with cervical cancer with respect to age
at diagnosis and clinical stage to assess whether HIV
infection was a predictor of advanced stage and
frequency of HPV detection.
Results
From April 1997 to October 1999, 141 women with
putative invasive cervical cancer seen at the hospitals
during the study period were asked to participate.
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because of lack of histological confirmation, leaving 132
case participants with histologically confirmed cervical
cancer. Of these 132, 114 had been recruited from the
first hospital and 18 from the second hospital. No signif-
icant differences were observed between these two
groups with respect to demographics, economic status,
the number of lifetime sexual partners, parity or HIV
infection status. A total of 135 consenting women were
enrolled as potential controls, representing approxi-
mately 70% of those eligible from those recruited. Of
these 135 women, 120 with normal cervical cytology
results were retained as controls; 14 women with cervi-
cal dysplasia (including Atypical Squamous Cells of
Undetermined Significance (ASCUS) and SIL) and one
with missing cytology results were excluded.
Characteristics of the study participants
Table 1 shows the demographic characteristics and dis-
tribution of risk factors for cervical cancer among cases
and control participants. Case participants were slightly
older than controls and had higher percentages with low
economic status and with no formal education. How-
ever, cases and controls had similar percentages who
reported having had first sex before 16 years and having
had > 6 sexual partners during their lifetime. Cigarette
smoking was rare both among cases and among control
participants. Twenty-two (16.7%) women with cervical
cancer and 10 (8.3%) control women were HIV-infected
(p = 0.048). None of the women with HIV infection
were on antiretroviral therapy (ART); during the study
period, ART was not routinely available in Côte d’Ivoire.
The five most prevalent types of HPV found in cervi-
cal cancer specimens were: HPV16 (45%), HPV18 (21%),
HPV45 (10%), HPV35 (8%), and HPV31 (3%). Other
high-risk HPV types found were: 33, 39, 51, 52, 53, 56,
58, 59, 66, and 68. The HPV types in cases and control
specimens were similar. However, the prevalence of
high-risk HPV infection was higher among women with
cervical cancer than among controls (89.4 vs. 31.1;
p < 0.0001).
Table 2 presents risk factors (covariates) of HIV infec-
tion among control participants. The percentage of
women with low economic status, or women with no
formal education did not significantly differ between
HIV-positive and HIV-negative controls. However, a
higher percentage of HIV-positive controls were from
low socioeconomic status. HIV infection was signifi-
cantly associated with age < 40 years, parity > 2, lifetime
number of sex partners > 6, and having high-risk HPV
infection.
High-risk HPV types were detected in all (100%) of
the HIV-positive women with cervical cancer and in 98/
110 (89%) of HIV-negative women with cervical cancer
(p = 0.1). In multivariate analysis, only HIV infection
was associated with HPV infection among controls (OR
= 3.0; 95% CI 0.7-13.5). A stronger association was
observed among younger women, but the number of
samples were small and the difference was not statistical
significant (OR = 6.8; 95% CI 0.5-98.0).
Risk factors for cervical cancer
Table 3 shows risk factors associated with cervical can-
cer in univariate and logistic regression analyses. In
univariate analyses, women with cervical cancer were
more likely to be either HIV-1-infected or HIV-2-
infected than were control women; however, these dif-
ferences were not statistically significant. In logistic
regression analysis, when controlling for age, low
socioeconomic status, and lifetime number of sex part-
ners > 6, the variables that remained associated with
cervical cancer were having high-risk HPV infection
(OR 23.0; 95% CI 10.5-50.2), parity > 2 (OR 5.5; 95%
CI 2.3-13.4), and low economic status (OR 2.4; 95% CI
1.2-4.9). However, when high-risk HPV infection was
removed from the model, HIV-1 infection or dual HIV
infection was associated with cervical cancer (OR 3.4;
95% CI 1.4-8.3). Although HIV-2 infection was also
associated with having cervical cancer, the association
did not achieve statistical significance, perhaps due to
the small number of HIV-2-positive women (OR 3.9;
95% CI 0.4-35.6). The positive association of HIV
infection and cervical cancer remained unchanged
when the analysis was restricted to case and control
participants with evidence of high-risk HPV DNA (OR
3.4; 95% CI 1.1-10.8).
Table 1 Characteristics of case and control participants
Characteristics Cases
(n = 132)
Controls
(n = 120)
p-value
Mean age (range) 46.7 (24-69)
%
43.5 (23-69)
%
0.02
Age > 40 years 68.2 56.7 0.059
Married 70.5 60.0 0.08
Low economic status 53.8 32.5 0.0001
No formal education 65.2 40.0 0.0001
Cigarette smoking 0 2.5 0.1
First sex < 16 years 37.9 31.7 0.3
Lifetime # of sex partners > 6 15.1 23.3 0.2
History of Pap smear 7.7 16.4 0.04
Parity > 2 87.1 62.5 0.0001
High-risk HPV 89.4 31.1 0.0001
HIV-positive 16.7 8.3 0.048
HIV-1-positive* 12.9 7.5 0.16
HIV-2-positive 3.8 0.8 0.1
* Includes 16 HIV-1-positive and only 1 dually-reactive among women with
cervical cancer, and 8 HIV-1-positive and only 1 dually-reactive among control
women
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were similar to controls with respect to economic status
and number of lifetime sexual partners. Table 4 shows
the risk factors for cervical cancer in separate logistic
regression analyses by age group. The risk factors asso-
ciated with having cervical cancer were having high-risk
HPV infection and parity > 2, both in women aged ≤ 40
years and in older women. However, HIV infection was
associated with cervical cancer only in younger women
(OR 4.5; 95% CI 1.5-13.6). There was no confounding of
the relationship by age, socioeconomic status, or lifetime
number of sexual partners. However, a potential interac-
tion between high-risk HPV and HIV infection could
not be assessed.
Table 5 shows the characteristics of HIV-positive and
HIV-negative women with cervical cancer. All HIV-posi-
tive case-participants had evidence of high-risk HPV infec-
tion. Among HIV-positive women, cervical cancer was
detected at a younger age (median age 39 years (range 24-
64)) than among HIV-negative women (median age
47 years (range 28-69)). Nevertheless, a similar percentage
(50% each) of HIV-positive and HIV-negative women had
advanced stage cervical cancer (Clinical Stage III or IV) at
diagnosis. Only 18% of HIV-positive women with cervical
cancer had CD4 counts below 200 cells/μl.
Although HIV-positive women with cervical cancer
had lower median CD4 counts than did HIV-positive
controls, the difference was not statistically significant
(376 cells/μl vs. 572 cells/μl: p = 0.6).
Discussion
HIV infection
The results in this case-control study are consistent with
established associations of cervical cancer with onco-
genic types of HPV infection and with a potential asso-
ciation of cervical cancer with high parity both for older
and younger women [5,18,33]. An association between
HIV infection and cervical cancer was also noted espe-
cially in women aged < 40 years, and this too is consis-
tent with published observations [34].
HIV-2 infection
Relatively unique to West Africa is the issue of HIV-2
infection. In this study, a higher prevalence of HIV-2
was observed among participants with cervical cancer
than among controls; however, the small numbers of
women with HIV-2 infectioni nt h ea b s e n c eo fH I V - 1
infection limited the power of the study to achieve a sta-
tistically significant result. An association of cervical car-
cinoma and HIV-2 infection has been previously noted
in studies conducted in West Africa [16,35]. Although
HIV-2 infection is associated with an increased likeli-
hood of cervical HPV clearance compared with that for
HIV-1 infection, after accounting for CD4 cell count,
women infected with HIV-2 do not appear to be appre-
ciably more likely to clear cervical HPV infection than
those infected with HIV-1 [36].
Table 2 Covariates of HIV infection among control participants
Variables HIV-Positive (n = 10) HIV-Negatives (n = 110) p-value
%%
Age group < 40 yrs 70.00 40.91 0.0578
No education 40.00 40.00 1.0000
Low economic status 60.00 28.18 0.0671
Cigarette smoking 10.00 1.82 0.2315
Age first sex < = 16 years 30.00 31.82 1.0000
Lifetime # of sex partners > 6 50.00 20.91 0.0521
History of Pap smear 10.00 17.98 0.4871
Parity > 2 30.00 65.45 0.0393
High-risk HPV* 55.56 28.87 0.1329
Low-risk HPV 0.00 9.28 0.4352
*HPV DNA results were available for 9 HIV-positive control participants
Table 3 Risk factors for cervical cancer in univariate and
logistic regression analyses
Risk Factors cOR (95%
CI)
aOR*(95%
CI)
aOR†(95%
CI)
Age group > 40 years 1.6 (1-1.7) 1.6 (0.7-3.6) 1.0 (1.0-1.04)
Low economic status 2.6 (1.3-5.3) 2.4 (1.2-4.9) 2.2 (1.3-3.8)
Lifetime # of sex partners
>6
0.6 (0.3-1.1) 0.8 (0.3-2.0) 0.8 (0.4-1.7)
Parity > 2 4.1 (2.0-8.4) 5.5 (2.3-13.4) 3.6 (1.7-7.4)
High-Risk HPV 21.2 (10.4-
42.9)
23.0 (10.5-
50.2)
NA
HIV-positive 2.2 (1.0-4.9) 1.8 (0.6-5.3) 3.4 (1.4-8.3)
HIV-1-positive 1.8 (0.8-4.3) 1.8 (0.6-5.6) 3.3 (1.2-8.7)
HIV-2-positive 4.7 (0.5-40.7) 0.9 (0.1-8.5) 3.9 (0.4-35.6)
cOR: Crude odds ratio in univariate analysis
aOR*: Adjusted odds ratio in logistic regression analysis controlling for high-
risk HPV
aOR†: Adjusted odds ratio in logistic regression analysis uncontrolled for high-
risk HPV
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Young age and advanced stage of cervical cancer in
HIV-infected women in this study were consistent with
published findings of rapidly progressive or more
advanced forms of cervical cancer at a young age [37].
A possible explanation is that HIV infection may facili-
tate the progression of cervical HPV lesions to cancer in
young women, and an inverse relationship of high-risk
HPV prevalence and age has been described [38]. How-
ever, among both the HIV-positive and HIV-negative
patients in this study, those with cervical cancer had
advanced clinical stages at the time of detection. This
may reflect low prevalence of screening, and in a setting
where preventive services are not developed, women
may seek treatment only when they have advanced dis-
ease. There was no evidence that the relationship
observed between HIV infection and cervical cancer
reflected higher risk behavior among younger women, as
numbers of sexual partners was adjusted for in the mul-
tivariate analysis.
Although HIV infection itself has been reported as a
risk factor for cervical cancer [5,18,37], it may be that
infection with high-risk types of HPV facilitates becom-
ing infected with HIV if exposed [39]. A higher preva-
lence of HPV infection in HIV-positive than in HIV-
negative women has been described [38]. Although the
association of cervical cancer with HIV infection was
observed only among the younger group of participants
i no u rd a t a ,i tm a yb et h a tt h el o w e rp r e v a l e n c eo fH I V
infection among older participants resulted in an insuffi-
cient number of HIV-infected participants to detect a
statistically significant difference in HIV-infection
between cases and controls.
Other biologic considerations
Previous findings support the biological plausibility of an
association between HIV infection and development of
cervical cancer [40]. It is possible that mechanisms asso-
ciated with HIV infection per se in the presence of HPV
infection, as well as the degree of HIV-induced immune
suppression, are both contributory to development of
invasive cervical cancer. HIV is present in vaginal cells,
and there is amplification of HPV expression by HIV tat
protein, which may explain a direct biologic interaction
between HIV and HPV [41], with HIV up-regulating the
persistence of HPV, leading to subsequent development
of SIL and invasive cervical cancer [42]. Degree of
immune suppression associated with HIV infection is
correlated with the risk of developing two other AIDS
defining cancers, Kaposi sarcoma and non-Hodgkin lym-
phoma [43]. Although there appears to be a correlation
between degree of HIV-induced immune suppression
and development of cervical neoplasia [40], in the study
presented here, HIV-infected women with cervical can-
cer did not have evidence of severe immune suppression
(CD4 counts < 200 cells/μl).
Limitations
In interpreting the results of this study, a few limitations
should be noted. First, controls who were recruited in
the oncology and surgical outpatient clinics may not
have been representative of the general population with
respect to the probability of having HIV infection; how-
ever, if the pathology that resulted in their seeking care
at the clinic had been related to HIV infection, the mea-
sure of effect would be biased towards the null hypoth-
esis of no association between HIV infection and
cervical cancer. Second, women who were recruited in
university hospitals may not have been representative of
women with cervical cancer in the general population in
terms of probability of having HIV infection; to adjust
for this potential bias (Berkson bias), control partici-
pants were selected from oncology and surgical
Table 4 Risk factors for cervical cancer by age group in logistic regression analysis
Risk Factors Age < 40 years Age > 40 years
Cases
(n = 42)
%
Controls
(n = 52)
%
OR* (95% CI) Cases
(n = 90)
%
Controls
(n = 68)
%
OR* (95% CI)
Low economic status 40.5 25.0 2.6 (0.7-9.6) 54.4 26.5 2.1 (0.8-5.3)
Lifetime sex partners > 6 35.7 32.7 2.0 (0.5-7.1) 5.6 16.2 0.2 (0.04-1.1)
Parity > 2 71.4 42.3 7.0 (1.9-25.7) 94.4 77.9 5.1 (1.2-21.9)
High-risk HPV 95.2 43.2 49.3 (8.2-295.7) 86.7 22.6 23.5 (9.1-60.6)
HIV-positive 35.7 13.5 4.5 (1.5-13.6) 7.8 4.6 2.0 (0.4-9.3)
* Adjusted odds ratio in logistic regression analysis
Table 5 Characteristics of HIV-positive and HIV-negative
women with cervical cancer
Characteristics HIV-Positive
(N = 22)
HIV-Negative
(N = 110)
Median Age (Range) 39 (24-64) 47 (28-69)
Clinical Stage III or IV 50% 50%
Median CD4 Counts (Range) 376 (82-1600) 833 (131-2248)
CD4 Counts < 200 cells/μl 18% NA
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the case patients were selected. Third, control-partici-
pants were on average younger and had a higher socioe-
conomic status than did case-participants; however,
these differences were addressed in multivariate analysis,
and therefore were unlikely to affect validity of results.
Fourth, the few cervical cancer specimens in which
high-risk HPV DNA was not identified were probably
false negatives, but their number was sufficiently small
that their inclusion in the case group would not have
appreciably altered the conclusions of this study.
Conclusions
The data presented here using confirmatory HIV testing,
HPV DNA testing, and histologically confirmed biopsies
support associations of cervical cancer with high-risk
HPV infection and with parity observed in previous stu-
dies. In addition, strong association of HIV infection
and cervical cancer was observed among young women,
with a high prevalence of high-risk HPV DNA in
women with HIV infection. In this study population,
few participants had ever had a Pap smear, and cervical
cancer was observed at a young age among women with
HIV infection in the absence of extreme immuno-
suppression. The findings overall add support to the
association of invasive cervical cancer among HIV-
infected persons, an association on which the recom-
mendation for annual cervical cytology screening in per-
sons with HIV infection is based.
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